Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood - United States
doi 10.1182/blood-2003-09-3220
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Imatinib Does Not Impair Specific Antitumor T-Cell Immunity in Patients With Chronic Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Plasmacytoid Dendritic Cell and Myeloid Dendritic Cell Function in Ageing: A Comparison Between Elderly and Young Adult Women

PLoS ONE
Multidisciplinary
2019English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Treatment of Chronic Myeloid Leukemia With Generic Imatinib in Patients From Northeastern Part of India

International Journal of Research in Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2019English

Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy